Crinetics Pharmaceuticals Inc. (NASDAQ: CRNX) reported preliminary net product revenue exceeding $5 million from its PALSONIFY drug during the fourth ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE